Case Overview: A 67-Year-Old Woman With Ovarian CancerApril 27th 2021
Chirag Shah, MD, MPH, an expert in gynecologic oncology, provides an overview of the case of a 67-year-old woman with ovarian cancer by reviewing the patient’s initial presentation, clinical work-up, and treatment.
A 67-Year-Old Woman With Ovarian CancerApril 27th 2021
Chirag Shah, MD, MPH, an expert in gynecologic oncology, reviews the case of a 67-year-old woman with ovarian cancer and discusses factors to consider when selecting therapy including the recent results of the PRIMA and NOVA trials of niraparib in patients with ovarian cancer.
FDA Approves Dostarlimab for Recurrent or Advanced dMMR Endometrial CancerApril 22nd 2021
The FDA has granted accelerated approval to dostarlimab-gxly for the treatment of adult patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR, as determined by an FDA approved test.
Frailty Score, Morphologic Subtype May Indicate Surgical Outcomes in Ovarian CancerApril 20th 2021
In an interview with Targeted Oncology, Katelyn Handley, MD, discussed two studies on ovarian cancer subtypes and the use of a frailty index to determine patient outcomes before, during, and after ovarian cancer debulking surgery.
FDA Okays Initiation of Endoxifen Study in Ovarian CancerApril 12th 2021
A patient with ovarian cancer has begun treatment with oral endoxifen, an active metabolite of tamoxifen, after a Safe to Proceed Letter was granted by the FDA, according to a press release by Atossa Therapeutics, Inc.
FDA Has Granted Priority Review to Tisotumab Vedotin for Advanced Cervical CancerApril 10th 2021
The FDA has accepted a biologics license application and granted it a priority review for tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Paclitaxel/Cisplatin for HIPEC During Debulking Correlates With Better Outcomes for Advanced Epithelial Ovarian CancerMarch 26th 2021
In women with advanced epithelial ovarian cancer treated in a single-institution study at the Cleveland Clinic, the addition of paclitaxel to cisplatin for hyperthermic intraperitoneal chemotherapy during interval debulking surgery was associated with improved oncologic outcomes compared with cisplatin alone.
Superior Efficacy Not Induced by the Addition of Olaparib to Cediranib in Advanced Endometrial CancerMarch 22nd 2021
No statistically significant difference was seen with the combination of olaparib and cediranib compared to cediranib alone in patients with recurrent, metastatic or persistent endometrial cancer.
Previously Treated Patients With Vulvar Squamous Cell Carcinoma Have Durable Responses on PembrolizumabMarch 21st 2021
Data from the KEYNOTE-158 study, presented at the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer, showed durable responses in heavily pretreated patients with vulvar squamous cell carcinoma regardless of their PD-L1 status.
Enzalutamide/Chemotherapy Triplet Shows Promising Activity in Advanced or Recurrent Endometrioid Endometrial CancerMarch 21st 2021
Patients with advanced or recurrent endometrioid endometrial cancer had promising clinical outcomes following treatment with the combination of enzalutamide and carboplatin plus paclitaxel in the phase 2 ENPAC clinical trial.
Niraparib Maintains PFS Improvement, But OS Data Are Limited in gBRCA+/- Ovarian CancerMarch 21st 2021
Niraparib administered as maintenance therapy showed clinical benefit lasting beyond first progression in patients with platinum-sensitive recurrent ovarian cancer with or without germline BRCA mutations, according to the final results of the ENGOT-OV16/NOVA study.
Both Germline, Somatic BRCA Mutations Benefit from Maintenance Olaparib in Platinum-Sensitive Relapsed Ovarian CancerMarch 21st 2021
Olaparib maintenance continues to show clinical activity in platinum-sensitive ovarian cancer, including in patients with somatic BRCA mutations and non-BRCA homologous recombination repair mutations.
Niraparib/Bevacizumab Combo Continues to Show Prolonged PFS in Patients With Advanced Ovarian CancerMarch 20th 2021
At the Society of Gynecological Oncology Virtual Annual Meeting on Women’s Cancer data from the phase II OVARIO study continued to show the progression free survival benefit for heavily pretreated patients with advanced ovarian cancer.
Pembrolizumab/Lenvatinib Leads to Survival Benefit in Previously Treated Advanced Endometrial Cancer, Regardless of MMR StatusMarch 20th 2021
Progression-free survival and overall survival were improved with pembrolizumab and lenvatinib when compared with chemotherapy in patients with advanced endometrial cancer who had received prior platinum-based chemotherapy in the phase 3 Study-309/KEYNOTE-775 trial.
CA-125 Tracking Has Potential to Identify Disease Progression on Olaparib and Bevacizumab in Ovarian CancerMarch 20th 2021
CA-125 surveillance alone could be used to detect disease progression in patients with advanced ovarian cancer and an abnormal CA-125 level at the beginning of frontline maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin), according to an analysis from the phase 3 PAOLA-1 that was presented at the SGO 2021 Annual Meeting on Women’s Cancer.
Rucaparib Improves PFS in BRCA+ Relapsed Ovarian Cancer in Confirmatory ARIEL4 TrialMarch 20th 2021
Compared with standard-of-care chemotherapy, treatment with the PARP inhibitor rucaparib led to a significant prolongation of progression-free survival and improved duration of response in patients with BRCA-mutated advanced, relapsed ovarian cancer, according to primary results from the phase 3 ARIEL4 trial.
Niraparib Shows Efficacy in Hard-to-Treat Patients With Newly Diagnosed Ovarian CancerMarch 19th 2021
Data from a post hoc analysis of the PRIMA/ENGOT-OV26/GOG-3012 phase III trial showed the efficacy of niraparib maintenance therapy for patients with ovarian cancer who had interval debulking surgery or visible residual disease.
Phase 3 Cemiplimab Trial in Cervical Cancer Stopped Early With Positive OS ResultsMarch 15th 2021
A phase 3 trial for cemiplimab monotherapy in comparison with chemotherapy in patients with recurrent or metastatic cervical cancer who previously received chemotherapy treatment is being stopped early due to a unanimous recommendation by the Independent Data Monitoring Committee due to positive overall survival results.
FDA Grants Priority Review to Injectable Pafolacianine Sodium to Identify Ovarian Cancer During SurgeryMarch 4th 2021
The FDA has accepted a New Drug Application for pafolacianine sodium injection and granted it Priority Review as a potential adjunct for identifying ovarian cancer during surgery.